Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?

Diabetes and Metabolism

Volumn 31, Issue 4 II, 2005, Pages

  Valensi, P ^a,b   Cosson, E ^a  

^a HÔPITAL JEAN VERDIER   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

Glycemic variability; Insulin analogs; Insulin detemir; Insulin effects; Insulin glargine; NPH insulin; Reproducibility

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING DRUG;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG EFFECT; DRUG MECHANISM; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; POSTPRANDIAL STATE; PRECIPITATION; REVIEW; RISK FACTOR; SUBCUTANEOUS TISSUE; TREATMENT OUTCOME;

EID: 25444465211     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(05)88265-5     Document Type: Review

References (19)

1. Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab 2005;31:7-13.
2. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000;23:45-50.
3. Ziel FH, Davidson MB, Harris MD, Rosenberg CS. The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption. Diabet Med 1988; 5:662-6.
4. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1988;21:1910-4.
5. Kurtzhals P, Havelund S, Jonassen I, Ribel U, Markussen J. Mode of action of fatty acid acylated insulin: a novel type of soluble, long-acting insulin analogues. Diabetes 1996;45 (Suppl. 1):222A [abstract].
6. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999;16:332-8.
7. Pieber TR, Plank J, Goerzer E, et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes 2002;51 (Suppl. 2):A53 [abstract].
8. Heise T, Nosek L, Biilmann Ronn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20.
9. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6.
10. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. A randomized clinical trial. Diabetes Care 2004; 27:1081-7.
11. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9.
12. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36.
13. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201.
14. Brange J. Design of insulin analogs for meal-related therapy. J Diabetes Compile 1993;7:106-12.
15. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 Asp-Insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-6.
16. Wiefels K, Hübinger A, Dannehland K, Gries FA. Insulin kinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analog (B28Asp). Horm Metab Res 1995;27:421-4.
17. Heinemann L, Weger C, Rave K, Stiefelhagen O, Rauhaus M, Heise T. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analog B28 Asp. Exp Clin Endocnnol Diabetes 1997;105:140-4.
18. Heller SR, Colagiurit S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004;21:769-75.
19. The Diabetes Control and Complications Trial Research Group. The absence of a glycaemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-98.